Clinical bottom line
Systemic treatments for chronic pruritic dermatoses in elderly patients show promise but require cautious use due to age-related pharmacokinetic changes and comorbidities. Recent evidence suggests that newer agents, including selective Janus kinase (JAK) inhibitors and biologics, may offer effective pruritus control with acceptable safety profiles in this population. However, data remain limited, and individualized risk-benefit assessment is essential. Clinicians should monitor closely for adverse events, drug interactions, and altered immune responses in elderly patients receiving systemic therapies for chronic pruritus.
What the evidence shows
Chronic pruritic dermatoses, such as atopic dermatitis, chronic urticaria, and prurigo nodularis, disproportionately affect elderly patients, often complicating management due to polypharmacy and comorbidities. Systemic treatment options have expanded, but evidence specifically addressing efficacy and safety in older adults is sparse.
Uchiyama et al. (2024) reported real-world effectiveness and safety of the JAK1 inhibitor abrocitinib in 12 Japanese patients with atopic dermatitis, including elderly individuals. The study demonstrated significant pruritus reduction and skin improvement with a tolerable safety profile, although the small sample size limits generalizability. Transcriptome analysis suggested modulation of immune pathways relevant to pruritus.
Older studies on systemic antihistamines, such as the comparison of HC 20-511 with dimetinden in chronic urticaria and pruritic dermatoses (Kcokkanen et al., 1975), indicate some symptomatic relief but highlight concerns about sedation and anticholinergic effects, which are particularly problematic in the elderly.
For psoriasis, which can present with pruritus, Piaserico et al. (2014) and Ghoreschi et al. (2014) reviewed systemic therapies in elderly patients, finding that biologics and conventional systemic agents can be effective and safe with careful monitoring. These findings may be extrapolated cautiously to pruritic dermatoses with inflammatory components.
Emerging therapies targeting pruritus pathways, such as KPL-716, an anti-IL-31 receptor antibody, have shown promise in early-phase studies for chronic pruritic diseases (Case Medical Research, 2019), but data in elderly cohorts are lacking.
Overall, systemic treatments can reduce pruritus severity and improve quality of life in elderly patients, but the evidence base is limited by small sample sizes, heterogeneous populations, and short follow-up durations.
Caveats and uncertainty
The current evidence is limited by a paucity of large, randomized controlled trials focused exclusively on elderly patients with chronic pruritic dermatoses. Most studies include small numbers of older adults or analyze them as subgroups, limiting statistical power and the ability to detect age-specific safety signals.
Age-related changes in drug metabolism, increased susceptibility to infections, and polypharmacy increase the risk of adverse events and drug interactions. For example, systemic JAK inhibitors may increase infection risk, which is a critical concern in elderly patients with immunosenescence.
Long-term safety data are scarce, and the balance between efficacy and tolerability remains uncertain in this population. Additionally, heterogeneity in pruritic dermatoses pathophysiology complicates extrapolation of findings across different conditions.
Finally, many studies originate from single centers or specific ethnic populations, such as the Japanese cohort in Uchiyama et al. (2024), which may limit applicability to broader elderly populations.
How this may change practice
Clinicians managing elderly patients with chronic pruritic dermatoses should consider newer systemic agents, including selective JAK inhibitors and biologics, as potential options when topical therapies and conventional treatments fail. However, treatment decisions must be individualized, weighing efficacy against risks related to age, comorbidities, and concomitant medications.
Close monitoring for adverse effects, especially infections and laboratory abnormalities, is essential. Initiating therapy at lower doses with gradual titration may improve tolerability. Collaboration with geriatric specialists and pharmacists can optimize medication management.
Future incorporation of emerging targeted therapies, such as IL-31 receptor antagonists, may expand options but requires validation in elderly cohorts.
Overall, this evolving evidence encourages cautious optimism for improved pruritus control in elderly patients, emphasizing the need for further dedicated research to guide safe and effective systemic treatment strategies.